GNE-502 is an orally active and potent estrogen receptor (ER) degrader, specifically designed for research on breast cancer.

GNE-502 (10 and 100 mg/kg; p.o.) possesses sufficient oral exposure to be tested in a WT MCF7 tumor xenograft model[1]. ..

GNE-502 shows dose dependent tumor growth inhibition at 10 mg/kg and 30 mg/kg, with tumor stasis at 100 mg/kg[1]. Animal Model: Mouse[1]Dosage: 10 and 100 mg/kg (Pharmacokinetic Analysis) Administration: P.o. Result: Possessed sufficient oral exposure to be tested in a WT MCF7 tumor xenograft model.